|
FY2022
12 months to Dec 31, 2022
|
FY2021
12 months to Dec 31, 2021
|
|
|---|---|---|
| Cash flows from operating activities | ||
| Net loss | ||
| Loss from continuing operations | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | ||
| Stock-based compensation expenses | ||
| Loss on early extinguishment of debt | ||
| Amortization of premiums and discounts on marketable securities, net | ||
| Noncash lease expense | ||
| Change in fair value of preferred stock purchase right liability | ||
| Change in fair value of preferred stock warrant liability | ||
| Common stock issued in exchange for services | ||
| Noncash interest expense | ||
| Changes in operating assets and liabilities: | ||
| Accounts receivable | ||
| Prepaid expenses and other current assets | ||
| Other assets | ||
| Accounts payable | ||
| Accrued compensation | ||
| Accrued expenses and other current liabilities | ||
| Payable to PLI | ||
| Deferred revenue | ||
| Operating lease liabilities | ||
| Net cash used in operating activities – continuing operations | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities | ||
| Purchase of property and equipment | ||
| Proceeds from maturities of short term investments | ||
| Purchases of short term investments | ||
| Net cash used in investing activities – continuing operations | ||
| Net cash used in investing activities | ||
| Cash flows from financing activities | ||
| Proceeds from issuance of convertible preferred stock, net of issuance costs | ||
| Repayment of debt | ||
| Proceeds from sale of common stock in initial public offering | ||
| Payment of financing costs | ||
| Proceeds from sale of common stock in public offerings, gross | ||
| Payment of public offering costs | ||
| Proceeds from issuance of common stock under employee stock purchase plan | ||
| Proceeds from issuance of common stock upon stock option exercises | ||
| Net cash provided by financing activities | ||
| Net increase in cash and cash equivalents | ||
| Cash and cash equivalents at beginning of period – continuing operations | ||
| Cash and cash equivalents at beginning of period – discontinued operations | ||
| Cash and cash equivalents cash at end of period | ||
| Cash and cash equivalents at end of period – continuing operations | ||
| Supplemental disclosures | ||
| Cash paid for income taxes | ||
| Cash paid for interest expense on Oxford debt | ||
| Right-of-use asset obtained in exchange for lease liabilities | ||
| Supplemental schedule of non-cash investing and financing activities | ||
| Conversion of convertible preferred stock into common stock upon completion of initial public offering | ||
| Reclassification of preferred stock purchase right liability to equity due to issuance of Series D convertible preferred stock | ||
| Reclassification of warrant liability to equity due to conversion from preferred stock warrant to common stock warrant upon completion of initial public offering | ||
| Issuance of Series D-2 convertible preferred stock for the settlement of deferred purchase price | ||
| Vesting of unvested issued common stock | ||
| Vesting of early exercised stock options | ||
| Public offering costs incurred, but not paid, included in accrued expenses and accounts payable | ||
| Costs incurred, but not paid, in connection with capital expenditures included in accounts payable | ||
| Preferred stock purchase right liability |
Loading...
